Reversion from HBeAg negative to HBeAg positive phenotype after interferon therapy for chronic hepatitis B.

被引：0
|
作者：
Kitis, G [1 ]
Ilias, A [1 ]
Kapetanos, D [1 ]
Kiriazis, G [1 ]
机构：
[1] G Papanikolaou Hosp, Salonika, Greece
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1761
引用
收藏
页码：601A / 601A
页数：1
相关论文
共 50 条
  • [21] Effect of the precore mutations on the HBeAg loss and viral breakthrough during lamivudine therapy in HBeAg-positive chronic hepatitis B.
    Kim, SS
    Hwang, YJ
    Kwon, KA
    Jung, MG
    Park, DK
    Kwon, OS
    Kwon, SY
    Kim, YS
    Koo, YS
    Kim, YK
    Choi, DJ
    Kim, JH
    HEPATOLOGY, 2003, 38 (04) : 723A - 723A
  • [22] Response to extended lamivudine treatment of HBeAg negative chronic hepatitis B.
    Andreone, P
    Hussain, MT
    Lok, AS
    Gramenzi, A
    Cursaro, C
    Lorenzini, S
    Porzio, F
    Margotti, M
    HEPATOLOGY, 2001, 34 (04) : 321A - 321A
  • [23] What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B
    Stephanos J. Hadziyannis
    Dimitrios Vassilopoulos
    Current Hepatitis Reports, 2012, 11 (2) : 65 - 69
  • [24] Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2006, 45 (03) : 457 - 460
  • [25] Long-term follow-up after initial response to interferon therapy in patients with HBeAg-negative chronic hepatitis B.
    Papatheodoridis, GV
    Manesis, E
    Hadziuannis, SJ
    HEPATOLOGY, 2000, 32 (04) : 378A - 378A
  • [26] Sustained response to the interferon therapy in HBeAg(+) chronic hepatitis B is not sustained
    Akarca, US
    Lebe, E
    Gunsar, F
    Karasu, Z
    Kilincsoy, N
    Ersoz, G
    Celebi, A
    Batur, Y
    JOURNAL OF HEPATOLOGY, 2002, 36 : 96 - 96
  • [27] Questioning the sustained response to the interferon therapy in HBeAg(-) chronic hepatitis B
    Akarca, US
    Lebe, E
    Ersoz, G
    Gunsar, F
    Karasu, Z
    Kilincsoy, N
    Celebi, A
    Batur, Y
    JOURNAL OF HEPATOLOGY, 2002, 36 : 96 - 96
  • [28] The impact of interferon-alfa (IFNa) therapy on liver histology in patients with HBeAg-negative chronic hepatitis B [HBeAg(-)CHB].
    Papatheodoridis, GV
    Cholongitas, E
    Kanta, E
    Petraki, K
    Ketikoglou, I
    Manesis, EK
    HEPATOLOGY, 2003, 38 (04) : 712A - 712A
  • [29] HbeAg-negative chronic hepatitis B results in more severe liver disease than HBeAg-positive chronic hepatitis B
    Mahtab, M.
    Rahman, S.
    Khan, M.
    LIVER INTERNATIONAL, 2006, 26 : 55 - 55
  • [30] Interferon therapy reduces cirrhosis and hepatocellular carcinoma in HBeAg positive chronic hepatitis
    Lin, Shi-Ming
    Lee, Chuan-Mov
    Chien, Rong-Nan
    Sheen, I-Shyan
    Chu, Chia-Ming
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A21 - A21
12345